Eloralintide vs Ipamorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideGrowth Hormone Peptides
Ipamorelin- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
- Half-Life
- ~7 days (estimated, long-acting design)
- 2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 100–300 mcg
- Frequency
- Once weekly
- Once to twice daily
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Increases lean muscle mass
- Enhances fat loss
- Improves recovery time
- Strengthens bones and joints
- Better sleep quality and REM sleep
- Enhanced skin elasticity
- Minimal impact on hunger or cortisol
- No cortisol or prolactin spike
- Clean GH release suitable for long-term protocols
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Injection site irritation
- Temporary water retention (mild)
- Possible hunger increase (milder than GHRP-6)
- Numbness or tingling in extremities (rare)
- Stacks With
- —
- —